Closure of a patent foramen ovale (PFO) to reduce recurrent events in patients with a PFO and cryptogenic stroke has proven to be highly successful, when the Amplatzer PFO occluder device or the Gore Cardioform or Helex devices were used, as demonstrated in 4 randomized controlled trials comparing PFO closure with antithrombotic therapy [ 1 2 3 4 ]. Based upon these findings, these PFO occluder devices have been given FDA approval and variable guideline recommendations. An earlier device, the CardioSeal, was not found to be effective in the Closure I trial [ 5 ]. Of note, among other challenges, the CardioSeal device was found to have the lowest effective closure rate of a variety of PFO closure devices and to have higher rates of post-implant atrial fibrillation [ 6 ].